← Back to Screener
XOMA Royalty Corporation Common Stock (XOMA)
Price$40.00
Favorite Metrics
Price vs S&P 500 (26W)0.26%
Price vs S&P 500 (4W)28.82%
Market Capitalization$463.38M
P/E Ratio (Annual)14.61x
All Metrics
P/CF (Annual)161.40x
Book Value / Share (Quarterly)$8.77
P/TBV (Annual)5.56x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)105.26%
Cash Flow / Share (Quarterly)$0.24
Payout Ratio (TTM)17.26%
Price vs S&P 500 (YTD)45.20%
Gross Margin (TTM)100.00%
Net Profit Margin (TTM)60.81%
EPS (TTM)$1.76
10-Day Avg Trading Volume0.17M
EPS Excl Extra (TTM)$1.76
Revenue Growth (5Y)12.15%
EPS (Annual)$1.76
Dividend / Share (Annual)$0.46
ROI (Annual)14.89%
Gross Margin (Annual)100.00%
Net Profit Margin (5Y Avg)-217.61%
Cash / Share (Quarterly)$7.02
P/E Basic Excl Extra (TTM)14.61x
Revenue Growth QoQ (YoY)57.87%
EPS Growth (5Y)8.80%
P/E Normalized (Annual)14.61x
ROA (Last FY)11.63%
Revenue Growth TTM (YoY)83.06%
EBITD / Share (TTM)$2.32
ROE (5Y Avg)-7.01%
Operating Margin (TTM)62.53%
Cash Flow / Share (Annual)$0.24
P/B Ratio4.46x
P/B Ratio (Quarterly)3.17x
Net Income / Employee (Annual)$2
EV / Revenue (TTM)9.39x
Net Interest Coverage (TTM)6.48x
ROA (TTM)13.05%
EV / EBITDA (TTM)11.74x
EPS Incl Extra (Annual)$1.76
Current Ratio (Annual)3.37x
Quick Ratio (Quarterly)3.34x
3-Month Avg Trading Volume0.31M
52-Week Price Return93.42%
EV / Free Cash Flow (Annual)170.48x
P/E Incl Extra (TTM)14.61x
Revenue / Employee (TTM)$4
Tangible BV / Share (Quarterly)$4.99
P/S Ratio (Annual)8.89x
Asset Turnover (Annual)0.19x
52-Week High$40.74
Operating Margin (5Y Avg)-226.62%
EPS Excl Extra (Annual)$1.76
Tangible BV CAGR (5Y)79.85%
26-Week Price Return9.00%
Quick Ratio (Annual)3.34x
13-Week Price Return35.25%
Total Debt / Equity (Annual)1.05x
Current Ratio (Quarterly)3.37x
Enterprise Value$489.452
Revenue / Share Growth (5Y)2.56%
Asset Turnover (TTM)0.21x
Book Value / Share Growth (5Y)2.59%
Revenue / Employee (Annual)$4
Inventory Turnover (Annual)0.00x
Pretax Margin (Annual)61.01%
Cash / Share (Annual)$7.02
3-Month Return Std Dev50.61%
Gross Margin (5Y Avg)75.37%
Net Income / Employee (TTM)$2
EBITDA CAGR (5Y)26.26%
EBITDA Interim CAGR (5Y)-15.39%
ROE (Last FY)30.50%
Net Interest Coverage (Annual)3.09x
EPS Basic Excl Extra (Annual)$1.76
P/FCF (TTM)53.46x
Receivables Turnover (TTM)15.49x
EV / Free Cash Flow (TTM)170.48x
Total Debt / Equity (Quarterly)1.05x
EPS Incl Extra (TTM)$1.76
Receivables Turnover (Annual)15.49x
ROI (TTM)15.21%
P/S Ratio (TTM)8.89x
Pretax Margin (5Y Avg)-221.56%
Revenue / Share (Annual)$2.90
Tangible BV / Share (Annual)$4.99
Forward P/E30.63x
Free OCF CAGR (5Y)-22.21%
Price vs S&P 500 (52W)58.33%
P/E Ratio (TTM)14.61x
Year-to-Date Return49.34%
5-Day Price Return2.74%
EPS Normalized (Annual)$1.76
ROA (5Y Avg)-2.95%
Net Profit Margin (Annual)60.81%
Month-to-Date Return26.59%
Cash Flow / Share (TTM)$-2.74
EBITD / Share (Annual)$2.26
Operating Margin (Annual)62.53%
LT Debt / Equity (Annual)0.93x
P/CF (TTM)161.40x
ROI (5Y Avg)-2.77%
P/E Excl Extra (TTM)14.61x
LT Debt / Equity (Quarterly)0.93x
EPS Basic Excl Extra (TTM)$1.76
P/TBV (Quarterly)5.56x
Payout Ratio (Annual)17.26%
P/B Ratio (Annual)3.17x
Dividend / Share (TTM)$0.46
Inventory Turnover (TTM)0.00x
Pretax Margin (TTM)61.01%
Book Value / Share (Annual)$8.77
Price vs S&P 500 (13W)32.39%
Net Margin Growth (5Y)6.09%
Dividend Yield (TTM)1.18%
Beta0.84x
P/FCF (Annual)161.40x
Revenue / Share (TTM)$2.88
ROE (TTM)32.61%
52-Week Low$20.00
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.20
4.20
4.09
4.09
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
XOMAXOMA Royalty Corporation Common Stock | 8.89x | 83.06% | 100.00% | 8.80% | $40.00 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
XOMA Royalty Corp acquires future revenue rights from pre-commercial drug candidates licensed to pharmaceutical and biotechnology companies. This non-dilutive funding model enables biotech firms to advance their internal drug development without equity dilution. The company operates globally across the United States, Europe, Asia Pacific, and Switzerland.